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Use of antibiotic-loaded polymethylmethacrylate
beads for the treatment of extracavitary prosthetic
vascular graft infections
Patrick A. Stone, MD, Paul A. Armstrong, DO, Dennis F. Bandyk, MD, Robert S. Brumberg, DO,
Sarah K. Flaherty, BS, Martin R. Back, MD, Brad L. Johnson, MD, and Murray L. Shames, MD,
Tampa, Fla
Purpose: This study was conducted to assess the efficacy of antibiotic-loaded polymethylmethacrylate (PMMA) beads in
the management of lower extremity extracavitary prosthetic arterial graft infection.
Methods: This was a retrospective review of 34 patients treated for vascular surgical site (VSS) infections involving 36
prosthetic lower extremity arterial bypasses using antibiotic-loaded PMMA beads and culture-specific parenteral
antibiotics for 4 to 6 weeks. Sites of graft infection were explored, debrided, and cultured. As determined from the results
of Gram’s stains of VSS purulence, PMMA powder was polymerized with an antibiotic (vancomycin, daptomycin, or
tobramycin/gentamicin, or a combination), molded into a chain of beads, and implanted adjacent to the infected graft
after debridement and pulsed-spray antibacterial lavage. All wounds were closed primarily with planned exploration to
verify sterilization before a graft preservation or in situ replacement procedure. Treatment outcomes, including wound
sterilization, were analyzed based on tissue culture isolates, procedures for persistent infection, and freedom from graft
infection.
Results: Cultures isolated 42 pathogens, (32 gram-positive, 9 gram-negative, 1 Candida albicans) with methicillin-
resistant Staphylococcus aureus (MRSA) cultured from 16 (44%) of 36 surgical site infections. As determined from the
initial operative Gram’s stain or a prior culture result, vancomycin PMMA beads were implanted in 29 of 36 VSS
infections at the first procedure; daptomycin (n 4) or tobramycin (n 3) beads were implanted in the rest. Repeat VSS
exploration and culture results led to an average of 2.5 antibiotic bead replacements before definitive treatment. A sterile
(no growth on tissue culture) VSS was achieved in 87% of cases before a graft preservation (n 16) or in-situ replacement
of an infected graft (n  20) procedure. No patient deaths occurred. Early and late limb salvage was 100%. Infection
recurred in 4 (11%) VSSs during a mean 23-month follow-up period, one within 3 months owing to unrecognized bowel
injury associated with in situ replacement of an aortofemoral graft limb.
Conclusion: Antibiotic-loaded PMMA beads may be a useful adjunct in the contemporary surgical management of VSS
infection involving a prosthetic graft. Wound sterilization was achieved in most VSSs before graft preservation or an
in-situ replacement procedure, including infections caused by MRSA, a pathogen isolated in half of the extracavitary
prosthetic graft infections. This preliminary trial shows the potential benefit of this new technique, but further study is
required to prove efficacy. (J Vasc Surg 2006;44:757-61.)Infection involving a prosthetic arterial graft presenting
either early (3 months) or later can result in significant
patient morbidity and mortality. Traditional management
of this vascular complication has stressed the importance of
intravenous administration of culture-specific antibiotics
with concomitant graft excision and extra-anatomic bypass
in cases of inadequate collateral circulation.1-3 Other vas-
cular groups have successfully used in-situ replacement,
with or without autologous vein grafts, and in selected
patients with an early prosthetic graft infection, graft pres-
ervation is possible.4-6 Failure of these procedures is most
commonly due to persistent vascular surgical site (VSS)
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doi:10.1016/j.jvs.2006.05.056infection. To achieve a sterile wound, most vascular sur-
geons have relied on povidone iodine wound irrigation
systems, serial wound debridements, and muscle flap cov-
erage of the preserved graft alone or in conjunction with an
in situ graft replacement procedure.6-9
The clinical application of antibiotic-loaded polymeth-
ylmethacrylate (PMMA) cement has been primarily by
orthopedic surgeons as an adjunct for the treatment of
tibial osteomyelitis or prosthetic joint infection.10,11 The
efficacy of local antibiotic delivery systems, in the form of
antibiotic-loaded PMMA beads, has also been shown in
reports on the management of complicated diabetic foot
infections and in preventing infection of ventricular assist
devices.12,13 Data on antibiotic bead usage for treating VSS
infections are limited and consist of small clinical series
using a variety of techniques, including permanent implan-
tation.14 During the past 5 years, our vascular group has
used antibiotic-loaded PMMA beads to deliver high drug
concentrations in VSSs during the initial management of a
prosthetic graft infection. The goal of antibiotic bead place-
ment is to sterilize the VSS and thus improve the safety and
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preservation procedures.
PATIENTS AND METHODS
Patient population. A query of our vascular registry
identified 34 patients with 36 lower extremity extracavitary
prosthetic graft infection sites in which antibiotic-loaded
PMMA beads were implanted at the time of VSS explora-
tion to confirm and treat infection. Use of antibiotic beads
began in 2001, and only patients with 3-months of
follow-up were included. The criteria for antibiotic bead
usage were clinical signs of infection involving an extracavi-
tary prosthetic graft implant site, including purulent wound
fluid, or positive Gram’s stain of perigraft fluid or tissue, or
both. Early (3-month) graft infections met criteria of the
Szilagyi type III prosthetic vascular graft infection (ie,
wound infection involving the graft). Patients treated by
emergent excision of an infected prosthetic graft were
excluded from analysis. These consecutive patients (20
men, 14 women) were primarily treated by one author
(D. F. B), with other faculty vascular surgeons (M. R. B.,
B. L. J., M. L. S.) participating in antibiotic bead exchange
and wound debridement procedures. The mean patient age
was 68.5 years (range, 47 to 89 years).
The presenting clinical manifestations of 25 early and
11 late VSS infections are shown in Table I. Most of the
infections (32 of 36) presented as a groin wound infection
and the remaining sites involved the entire infrainguinal
prosthetic bypass. All patients were initially prescribed
broad-spectrum parenteral antibiotics with subsequent
changes determined by wound and graft culture results and
susceptibility testing. After hospital discharge, all patients
received parenteral or oral culture-specific antibiotics for a
minimum of 6 weeks.
The types of prosthetic graft infections treated included
the extracavitary segment of an aortofemoral graft limb in
16, polytetrafluoroethylene (PTFE) femorofemoral graft in
6, PTFE axillofemoral graft–groin segment in 1, infrain-
guinal PTFE bypass in 11, and 2 multigraft infections
(PTFE femorofemoral and infrainguinal bypass, and poly-
ester aortobifemoral with PTFE infrainguinal bypass). Two
patients presented with bilateral groin wound infections
after polyester aortobifemoral bypass. One patient required
Table I. Clinical presenting signs of 25 early and 11 late
appearing vascular surgical sites with extracavitary
prosthetic graft infection
Presenting sign
Early infection
3 months
Late infection
3 months
Wound infection 14 —
Pseudoaneurysm 1 —
Infected hematoma 3 —
Abscess 3 8
Groin sinus tract — 2
Infected lymphocele 4 1emergent treatment owing to pseudoaneurysm hemor-rhage of a femoral interposition graft and underwent PTFE
in situ graft replacement with antibiotic bead implant as a
bridge procedure prior to staged deep femoral vein replace-
ment. All other procedures were performed as nonemer-
gent treatment of a VSS infection.
Operative technique. Surgical exploration of the
surgical site was performed to obtain Gram’s stain and
culture testing of perigraft tissue and fluid and to confirm
involvement of the vascular prosthesis. All necrotic or
infected tissue was debrided, followed by pulse lavage
irrigation of the VSS using 3 liters of Clorpactin (United-
Guardian, Inc, Hauppauge, NY) (oxychlorosene so-
dium) solution (6 g/3 L).
Antibiotic beads were made in the operating room by
using PMMA powder (40 g) polymerized with methacry-
late (20 mL) to which vancomycin (2 g) or daptomycin
(1 g; Cubist Pharmaceuticals, Lexington, Mass) was added
for gram-positive organisms, and an aminoglycoside (to-
bramycin, 1 g; gentamicin, 1 g) if gram-negative organisms
were present. Antibiotic-loaded PMMA cement was placed
in a 5-mm bead mold and attached to 2-0 stainless steel.
The hardened antibiotic beads were then implanted as a
bead-string adjacent to the infected graft segment (Fig 1).
Subcutaneous tissue was closed over the graft and beads
using absorbable sutures, and when possible, skin was
approximated with monofilament nylon sutures.
Typically, the VSS was re-explored 3 days later (range,
3 to 6 days), after culture results were available (Fig 2). The
VSS and graft were inspected for invasive infection, tissue
cultures were obtained, additional tissue was débrided if
necessary, and antibacterial lavage of the VSS was per-
formed. The antibiotic beads were removed and replaced
with new antibiotic-loaded PMMA beads according to
antibiotic susceptibility testing of the prior VSS culture
results. The replaced antibiotic beads were attached to a 0
polypropylene suture and brought out through a separate
skin incision to allow removal at bedside.
If the second VSS culture exhibited no growth (ie, was
Fig 1. Antibiotic-loaded polymethylmethacrylate beads implanted
adjacent to an infected polytetrafluoroethylene graft segment.sterile) the implanted antibiotic beads were removed at
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sisted of graft preservation by wound closure with muscle
flap coverage of the prosthetic graft or in situ replacement
of involved graft with autologous vein or rifampin-soaked
PTFE (Gel-Seal Vascutek, Somerset, NJ) and sartorius
muscle flap coverage. If the wound cultures were not sterile
at the time of re-exploration, new antibiotic beads were
inserted. In some instances, the operating surgeon pro-
ceeded with in situ vein replacement at this time and beads
were removed 5 to 7 days later. In general, sterile VSS
cultures were required before final graft preservation or an
in situ prosthetic graft replacement procedure.
Wound sterilization was defined by an absence of bac-
terial growth by tissue culture in a in VSS with tissue that
appeared healthy and viable. Our treatment algorithm was
used to complete the surgical intervention. Graft preserva-
tion was attempted on all early (3 month) graft infections
with a single bacterial isolate, such as Staphylococcus aureus,
and segmental graft involvement. For polymicrobial and all
late-appearing graft infections, in-situ graft replacement
was typically performed. Culture-specific antibiotic treat-
ment was continued for a mean 5.3 weeks (range, 4 to 8
weeks).
RESULTS
Tissue cultures obtained at the initial VSS exploration
isolated 43 pathogens (Table II). Methicillin-resistant S
aureus (MRSA) was cultured from 16 (44%) of the 36
infected graft sites. The initial Gram’s stain of perigraft fluid
and tissue identified 30 gram-positive VSSs, three gram-
negative, and no organisms in three. All patients received
PMMA antibiotic-loaded beads at the first operative proce-
dure: vancomycin in 29 VSSs, daptomycin in four, and
vancomycin/tobramycin in three. Gram-positive infection
was confirmed in 32 (88%) of 36 VSSs, including isolates of
VSS Exploration,
Gram’s Stain & Culture, 
Wound Debridement
Type of Antibiotic Bead
Implanted Based on  
Gram’s Stain Result
VSS Re-exploration
in 3 days 
Gram’s Stain – Culture 
(Negative)
Gram’s Stain - Culture 
(Positive)
In Situ Graft Replacement Graft Preservation 
Autogenous Vein 
Rifampin-soaked PTFE 
+/- Sartorius Muscle Flap
Wound Closure +/- 
Sartorius Muscle Flap 
Fig 2. Treatment algorithm for implantation of antibiotic-loaded
beads in the vascular surgical sites (VSS) with infected prosthetic
vascular grafts.MRSA in 16, methicillin-sensitive S aureus in 7, S epider-midis in 7, enterococcus–Streptococcus faecalis in 2, and
-hemolytic Streptococcus in 1. Seven gram-negative iso-
lates were cultured, including strains of Pseudomonas
aeruginosa (n  5), Escherichia coli (n  2), Proteus, and
Morganella sp. One VSS infection isolated only Candida
albicans.
The treatments used for 25 early and 11 late extra-
cavitary graft infections are summarized in Fig 3. Graft
preservation was performed in 16 VSSs and in situ replace-
ment in 20, with sartorius muscle flap coverage of the graft
used in 12 (33%). Wound debridement with antibiotic
beads implant was the sole treatment in 10 of 25 early and
2 of 11 late graft infections, and in situ graft replacement
was performed in 10 early and 9 late graft infections.
VSS sterilization was achieved after the initial debride-
ment procedure as documented by tissue culture in 18
(58%) of 31 VSSs tested. Five patients did not have cultures
and underwent an in situ replacement of the infected graft
using autologous vein. Overall, wound sterilization was
Table II. Type and (number) of bacterial and fungal
isolates recovered from 36 vascular surgical sites with
extracavitary prosthetic graft infection
Type N
Gram-positive
Methicillin resistant S. aureus 16
Methicillin sensitive S. aureus 7
S. epidermidis 7
Enterococcus–S faecalis 2
-hemolytic Streptococcus 1
Gram-negative
Pseudomonas sp 5
Escherichia coli 2
Morganella morganii 1
Proteus 1
Other
Candida albicans 1
Fig 3. Types of management used to treat 25 early and 11
late-appearing extracavitary prosthetic graft infections. RS,
Rifampin-soaked polytetrafluoroethylene or polyester gelatin-
impregnated graft; SMF, sartorius muscle flap; AL, autologous
vein; ABF, aortobifemoral.documented in 27 (87%) of 31 VSSs before graft preserva-
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beads were replaced a mean of 2.5 times (range, 1 to 4
times).
Outcomes at 30-days included no patient deaths, aller-
gic reactions, or limb loss. One in situ replacement proce-
dure failed owing to an unrecognized small-bowel injury.
This required reoperation and bowel repair, and the deep
vein replacement of the aortofemoral graft was successful.
The average length of hospitalization was 18 days (range, 5
to 56 days).
No patient was lost to follow-up during a mean 23-
month postoperative period. At last follow-up, 33 patients
had healed VSS without signs or symptoms of infection.
Three patients died within 3 months after discharge of
causes not directly related to VSS infection or its treatment.
One patient with a healing VSS groin wound had cardio-
pulmonary arrest at home, and the remaining two patients
with clinical signs of VSS infection died from cerebrovas-
cular events (stroke, subarachnoid hemorrhage).
Recurrent graft infection developed in four of the 31
surviving patients at a mean time interval of 11 months
(range, 6 to 15months). Pseudoaneurysms occurred in two
patients at the treated VSS site at 6 and 12 months and
required deep vein replacement of an aortofemoral graft
limb for MRSA and Candida infection, respectively. One
patient presented with recurrent femorofemoral graft infec-
tion 15 months after a graft preservation procedure and
underwent deep vein replacement of the graft infected by
P aeruginosa. Two of three patients treated for recurrent
VSS infections had persistent positive cultures at the time of
their in situ replacement procedure. The last patient treated
for recurrent graft infection presented 15 months after in
situ replacement of an aortofemoral graft limb with infec-
tion proximal to treated VSS owing to a retained, throm-
bosed aortofemoral graft segment that had not been previ-
ously excised. This infected segment was excised, and no
involvement with the treated VSS was identified.
DISCUSSION
Management of prosthetic graft infection remains a
difficult clinical problem, especially with the emergence of
resistant bacterial strains such as MRSA. Vascular surgeons
should suspect MRSA infection in patients presenting with
both early and late VSS infection. The prevalence of MRSA
infection was 44% in this series, similar for extracavitary graft
infections presenting early (11 of 25) and late (5 of 11). This
incidence is similar to recent audits of vascular infection
that reported 53% of S aureus infections were methicillin
resistant. The overall MRSA vascular surgical site infection
rate was 4%. The incidence was higher after infrainguinal
procedures than after femorofemoral or aortofemoral by-
pass grafting.15 Factors associated with VSS infection in-
cluded MRSA colonization, a groin implant site, redo
procedure, and no MRSA antibiotic prophylaxis. The
emergence of MRSA colonization on vascular surgery units
with a prevalence of 7% to 8% suggests a change in antibi-
otic prophylaxis may be appropriate, particularly in patients
having prosthetic grafts implanted in the groin.16Patients with extracavitary VSS infection typically
present clinical signs in the groin region, with infection
involving the femoral segment of an aortofemoral graft
limb, an extra-anatomic (femorofemoral, axillofemoral), or
infrainguinal prosthetic arterial bypass. Most patients are
not septic, and anastomotic hemorrhage is uncommon
unless the patient or the surgeon has procrastinated.
Treatment has traditionally involved extra-anatomic
bypass with graft excision.1,17 However, many patients
presenting with an extracavitary graft infection have under-
gone complex arterial repairs and the options for ex-situ
revascularization are limited or not possible. These circum-
stances have prompted vascular surgeons to attempt graft
preservation treatment or perform in situ replacement us-
ing autologous vein or an antibiotic-impregnated graft.
Calligaro et al6 reported a 20-year experience using a
graft preservation strategy that included serial debridement
and povidone-iodine or antibiotic-soaked dressing changes
three times daily to sterilize the VSS and promote granula-
tion tissue coverage over exposed bypass grafts.6 Cited
benefits included a simpler method of treatment, decreased
amputation rates, and low incidence of graft-related hem-
orrhage.
In our treatment algorithm, antibiotic beads are used as
adjunct to surgical debridement and tissue cleansing to
sterilize the VSS and prosthetic graft by providing high
drug concentration to adjacent tissues and the biomaterial
surfaces. Treatment is done with the VSS wound closed,
avoiding the necessity of an exposed arterial graft, intensive
care unit monitoring, and multiple daily dressing changes.
VSSs are explored every 3 to 5 days to re-evaluate for and
treat invasive infection by performing further tissue de-
bridement if necessary, and to obtain tissue culture to
determine if perigraft tissue sterilization has been achieved.
Once the VSS culture is negative, a graft preservation
procedure can be completed, typically by performing mus-
cle flap coverage of the treated graft segment and suturing
the wound closed; or in situ replacement of extracavitary
graft is performed. This approach ensures that wound
closure or an arterial reconstruction is not performed in the
setting of an invasive wound infection.
The implantation of antibiotic-loaded PMMA beads
was effective in producing a sterile VSS in the presence of a
patent, prosthetic arterial bypass. After a single implanta-
tion of antibiotic beads, negative tissue cultures were ob-
tained in two thirds of VSSs; and after serial bead ex-
changes, 87% of VSS were sterile by culture. The benefit of
VSS sterilization is based on the hypothesis that a wound
with minimal colonization will exhibit less healing prob-
lems and thus improve the clinical success of graft preser-
vation or in situ replacement procedures. Our treatment
outcomes with antibiotic beads were better that those
reported by Calligaro et al6 and their graft preservation
strategy, including 30-day mortality (0% vs 12%), limb loss
(0% vs 4%), and wound healing rates (89% vs 71%).6 Of
note, no graft-related hemorrhage occurred in this series.
The incidence of secondary procedures for recurrent
graft infection was low. Five (15%) patients developed a
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involved the treated VSS. Two were the result of technical
error consisting of a small-bowel injury during an in situ
replacement procedure, and failure to remove a prior
thrombosed aortofemoral graft limb segment. Three recur-
rent infections involving the treated VSS site, all developed
beyond 6-months and were managed by deep vein replace-
ment of the infected prosthetic graft segment. Two patients
had persistent positive wound cultures despite antibiotic
beads placements at the time of their in situ replacement.
CONCLUSION
The clinical application of antibiotic beads in the man-
agement of VSS infection deserves further study. The effi-
cacy of this type of local antibiotic delivery system in
treating or preventing infection has been demonstrated in
experimental animal models and in clinical applications for
the treatment of prosthetic joint infection, tibial osteomy-
elitis, and diabetic foot infection.9-11,13 Our vascular group
chose not to performed a randomized study with a control
group receiving no antibiotic beads, primarily because the
number of enrolled subjects required to demonstrate a
treatment difference is not feasible at a single institution.
Rather, our approach has been to incorporate this treat-
ment adjunct into clinical care in selected patients present-
ing with VSS infection, and then carefully evaluate out-
comes associated with graft preservation or in situ
replacement procedures by reporting on factors associated
with success or failure of treatment. We believe that at-
tempts to achieve VSS sterilization, including the use of
antibiotic beads, is clinically useful and should enhance the
safety of caring for patients with extra-cavitary graft infec-
tions.
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